Osteopetrosis

Definition

Osteopetrosis (marble bone disease, Albers-Schonberg disease) is a group of rare inherited skeletal disorders characterized by defective osteoclast-mediated bone resorption. This leads to accumulation of primary spongiosa and calcified cartilage, resulting in generalized skeletal sclerosis. Despite increased radiographic density, the bone is structurally abnormal and paradoxically brittle.

Epidemiology

Genetics

Sclerosing Bone Disorders

Key Distinguishing Points:

• Pyknodysostosis: Toulouse-Lautrec had this; characterized by short stature, fragile bones, but with ACRO-OSTEOLYSIS (absent in osteopetrosis) and open fontanelles
• Engelmann Disease: Affects diaphyses primarily, causes pain and weakness, autosomal dominant
• Melorheostosis: Unilateral, follows sclerotome/dermatomal pattern, looks like dripping candle wax

Disease-Related Complications

Surgical Complications

BMT Complications

• Graft-versus-host disease (GVHD)
• Graft failure
• Infection (during immunocompromised period)
• Veno-occlusive disease
• Late effects of conditioning chemotherapy

Global Epidemiology

There is no high-level (RCT) guidance for this rare disease; practice rests on registry data and expert consensus.

Consensus Positions Across Societies

Registries and Networks

HSCT outcomes are pooled through international transplant registries (CIBMTR in North America, EBMT in Europe), which together generated the largest osteopetrosis transplant cohort to date. Unrelated-donor matching relies on national and international marrow donor registries. Rare-bone-disease reference networks (for example ERN-BOND in Europe) coordinate diagnosis, genetic confirmation and multidisciplinary care.

High- vs Limited-Resource Practice Variation

• Well-resourced settings: next-generation sequencing gene panels, early HSCT in infancy, skull-base and ophthalmology services, and locked-plate plus external-fixation inventories for fracture surgery.
• Limited-resource settings: diagnosis is often clinical and radiographic; transplant access may be delayed or unavailable, shifting care toward transfusion support, infection control and conservative fracture management. Consanguinity raises ARO incidence, so genetic counselling and antenatal diagnosis carry high value where available.

The CA2 gene appears in the pathophysiology table, the intermediate-forms tab, the cheat sheet and the genetics differential, but this distinct, highly examinable syndrome is never developed - and it is the one osteopetrosis variant with a signature systemic triad.

• A distinct autosomal-recessive triad. Carbonic anhydrase II (CA2) deficiency causes a recognisable syndrome of (1) osteopetrosis + (2) renal tubular acidosis (RTA) + (3) cerebral (basal ganglia) calcification - often remembered together, with developmental delay/intellectual disability and short stature completing the picture. It is also called Guibaud-Vainsel syndrome or "marble brain disease".
• Why one enzyme does all three. Carbonic anhydrase II generates the protons (H⁺) that the osteoclast's proton pump secretes to acidify the resorption lacuna - so its loss impairs bone resorption (osteopetrosis). The same enzyme is needed for renal tubular acid handling (both proximal and distal), producing a mixed proximal + distal RTA; and it is expressed in the brain, where its deficiency is associated with the characteristic basal-ganglia calcification. One shared biochemical step, three organ systems.
• How it differs from "classic" osteopetrosis - and why it matters. Unlike TCIRG1/CLCN7 disease, CA2 deficiency is milder in its skeletal severity (marrow failure is usually NOT life-threatening), the sclerosis may even diminish with age, and crucially it is NOT curable by haematopoietic stem-cell transplant - because the defect is a systemic enzyme deficiency, HSCT corrects the marrow-derived osteoclast but not the renal or cerebral disease. Management is therefore supportive: treat the RTA (alkali therapy), manage fractures, and monitor growth/development.

The Shapiro evidence card notes "thickened growth plates if there is superimposed rickets" and the pathophysiology tab lists "rickets-like features paradoxically possible", but the topic never explains how a disease of too much bone can coexist with rickets - a classic exam curveball.

• It is real, and it makes mechanistic sense. "Osteopetrorickets" is the coexistence of rachitic (unmineralised) growth-plate changes on a background of dense osteopetrotic bone - seen particularly in severe infantile ARO. The key is that osteopetrosis is a defect of resorption, not of mineral supply, and the two problems attack different compartments.
• Why the osteoclast defect causes a mineralisation failure. Normal osteoclasts liberate calcium (and phosphate) from bone into the blood; when they cannot resorb, the skeleton behaves as a calcium "sink" that traps mineral and cannot release it, so despite radiodense bones the child can become hypocalcaemic. The hypocalcaemia drives secondary hyperparathyroidism, and the low available mineral at the growth plate produces genuine rickets (widened, frayed, cupped physes) - hence dense metaphyses with rachitic growth plates side by side.
• Clinical consequences to recognise. The hypocalcaemia can be symptomatic - tetany and seizures in infancy (a feature specifically noted in ARO) - and the picture can be worsened by coexisting nutritional vitamin-D deficiency. Treatment is calcium and vitamin D/calcitriol to correct the mineral deficit (calcitriol may additionally stimulate residual osteoclasts); this is one reason mineral status is monitored closely, and it does not contradict the "no antiresorptives" rule.

The rarity of osteopetrosis means most management rests on registries and expert opinion rather than randomised trials. Several genuine areas of debate persist:

• Optimal timing and conditioning for HSCT. Earlier transplantation in infancy is associated with better outcomes, but the ideal age threshold, conditioning regimen, and donor hierarchy beyond matched siblings remain unsettled. Graft failure and hepatic/pulmonary toxicity are the dominant limitations rather than the transplant decision itself.

• Reversibility of neurosensory deficits. Whether established optic atrophy or hearing loss can be salvaged by transplant or surgical decompression is uncertain; most evidence suggests vision rarely improves once atrophy is fixed, which is why decompression is considered only before established damage.

• Role of optic-canal decompression. Indications and benefit are inconsistent across centres, and it is reserved for selected, progressive cases rather than offered routinely.

• Pharmacological alternatives to transplant. Interferon-gamma-1b offers only modest, mainly supportive benefit; recombinant RANKL for osteoclast-poor (TNFSF11) disease and gene therapy for TCIRG1/CLCN7 remain investigational, with limited human data.

• Denosumab in osteopetrosis. As a disease therapy it is contraindicated (it suppresses osteoclasts), yet it has been explored narrowly for transplant-related hypercalcaemia - a nuance that is easy to misstate.

• Fracture fixation strategy. There is no consensus trial comparing plating, intramedullary fixation, and external fixation; choice is individualised, and the often-quoted precise nonunion percentages are extrapolated from small series rather than robust cohort data.